Featured: Annual Report and Accounts and Notice of AGM
Annual Report and Accounts and Notice of AGM
Appointment of joint broker
Board change
Preliminary Results for the Year Ended 31 March 2017
FDA approves cryopreserved formulation of ReNeuron’s retinal stem cell therapy candidate
at 2017-08-17 15:55:48
15 minute delayed share price from London Stock Exchange provided by Euroland.
